RedHill Biopharma (RDHL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.48, -3.79% vs the prior close of $0.50.
- Volume 84.72K shares, 0.0x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RDHL slides 3.8% to $0.48. Closed at $0.48, -3.79% vs the prior close of $0.50. Day range $0.48–$0.51, opened at $0.50.
RDHL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RDHL slides 3.8% to $0.48
- Closed at $0.48, -3.79% vs the prior close of $0.50. Day range $0.48–$0.51, opened at $0.50.
- Volume was 84.72K shares, 0.0x its 50-day average of 2.62M — lighter than usual.
- Price is -18.4% vs its 50-day average ($0.59) and -43.6% vs its 200-day average ($0.85).
- 52-week range $0.44–$2.14; today's close sits at 3% of that range, 77.6% below the 52-week high.
Oct 15, 2026 — RDHL rises 2.7% to $0.50
- Closed at $0.50, +2.67% vs the prior close of $0.49. Day range $0.48–$0.51, opened at $0.49.
- Volume was 59.40K shares, 0.0x its 50-day average of 2.62M — lighter than usual.
- Price is -15.5% vs its 50-day average ($0.59) and -41.5% vs its 200-day average ($0.85).
- 52-week range $0.44–$2.14; today's close sits at 4% of that range, 76.7% below the 52-week high.
Oct 14, 2026 — RDHL slides 5.6% to $0.49, 4 down days in a row
- Closed at $0.49, -5.63% vs the prior close of $0.51. Day range $0.48–$0.51, opened at $0.50.
- Volume was 84.70K shares, 0.0x its 50-day average of 2.62M — lighter than usual.
- Price is -18.2% vs its 50-day average ($0.59) and -43.3% vs its 200-day average ($0.86).
- 52-week range $0.44–$2.14; today's close sits at 3% of that range, 77.3% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — RDHL slides 3.4% to $0.51, 3 down days in a row
- Closed at $0.51, -3.38% vs the prior close of $0.53. Day range $0.50–$0.53, opened at $0.51.
- Volume was 81.60K shares, 0.0x its 50-day average of 2.62M — lighter than usual.
- Price is -13.8% vs its 50-day average ($0.60) and -40.1% vs its 200-day average ($0.86).
- 52-week range $0.44–$2.14; today's close sits at 5% of that range, 75.9% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: 6-K, 424B5.
Oct 12, 2026 — RDHL dips 1.1% to $0.53
- Closed at $0.53, -1.11% vs the prior close of $0.54. Day range $0.51–$0.56, opened at $0.54.
- Volume was 70.00K shares, 0.0x its 50-day average of 2.62M — lighter than usual.
- Price is -11.1% vs its 50-day average ($0.60) and -38.2% vs its 200-day average ($0.86).
- 52-week range $0.44–$2.14; today's close sits at 6% of that range, 75.1% below the 52-week high.
Oct 9, 2026 — RDHL slides 6.7% to $0.54
- Closed at $0.54, -6.75% vs the prior close of $0.58. Day range $0.52–$0.59, opened at $0.55.
- Volume was 379.30K shares, 0.1x its 50-day average of 2.61M — lighter than usual.
- Price is -10.5% vs its 50-day average ($0.60) and -37.8% vs its 200-day average ($0.87).
- 52-week range $0.44–$2.14; today's close sits at 6% of that range, 74.8% below the 52-week high.
Oct 8, 2026 — RDHL jumps 21.9% to $0.58 on 6.9x normal volume
- Closed at $0.58, +21.94% vs the prior close of $0.47. Day range $0.44–$0.69, opened at $0.50.
- Volume was 15.75M shares, 6.9x its 50-day average of 2.30M — unusually heavy trading.
- Price is -4.3% vs its 50-day average ($0.60) and -33.5% vs its 200-day average ($0.87).
- 52-week range $0.44–$2.14; today's close sits at 8% of that range, 73.0% below the 52-week high.
Oct 7, 2026 — RDHL dips 2.1% to $0.47, a 52-week low, 3 down days in a row
- Closed at $0.47, -2.07% vs the prior close of $0.48. Day range $0.47–$0.50, opened at $0.47.
- Volume was 36.10K shares, 0.0x its 50-day average of 2.30M — lighter than usual.
- Price is -21.8% vs its 50-day average ($0.61) and -45.7% vs its 200-day average ($0.87).
- 52-week range $0.47–$2.14; today's close sits at 1% of that range, 77.9% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: 6-K.
Oct 6, 2026 — RDHL dips 1.8% to $0.48
- Closed at $0.48, -1.83% vs the prior close of $0.49. Day range $0.47–$0.50, opened at $0.50.
- Volume was 57.90K shares, 0.0x its 50-day average of 2.30M — lighter than usual.
- Price is -20.8% vs its 50-day average ($0.61) and -44.7% vs its 200-day average ($0.88).
- 52-week range $0.47–$2.16; today's close sits at 1% of that range, 77.6% below the 52-week high.
Oct 5, 2026 — RDHL dips 1.4% to $0.49
- Closed at $0.49, -1.40% vs the prior close of $0.50. Day range $0.49–$0.51, opened at $0.50.
- Volume was 90.70K shares, 0.0x its 50-day average of 2.30M — lighter than usual.
- Price is -19.9% vs its 50-day average ($0.62) and -43.9% vs its 200-day average ($0.88).
- 52-week range $0.47–$2.26; today's close sits at 2% of that range, 78.2% below the 52-week high.
Oct 2, 2026 — RDHL jumps 4.2% to $0.50
- Closed at $0.50, +4.17% vs the prior close of $0.48. Day range $0.49–$0.51, opened at $0.51.
- Volume was 130.20K shares, 0.1x its 50-day average of 2.29M — lighter than usual.
- Price is -19.1% vs its 50-day average ($0.62) and -43.3% vs its 200-day average ($0.88).
- 52-week range $0.47–$2.60; today's close sits at 2% of that range, 80.8% below the 52-week high.
RDHL latest news & SEC filings
Every SEC filing by or about RDHL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 13, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 7, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Raday Gilead sold 14,310,000 shares at $0.00 (≈$1.43K) on Oct 1, 2026; now holds 176,910,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 30, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 1, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 31, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 7, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 6, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 28, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 13, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Jul 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Raday Gilead sold 14,130,000 shares on Jul 10, 2026
- Raday Gilead sold 14,130,000 shares on Jul 10, 2026
- Raday Gilead sold 14,130,000 shares on Jul 10, 2026
- Raday Gilead sold 14,130,000 shares on Jul 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 2, 2026 · Form F-3 — F-3 filing
F-3 filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade RDHL
- How much it moves: over the last 20 sessions the average daily move was 3.72% (largest 21.9%). That is a volatile stock.
- Liquidity: about 916.80K shares (≈$440.15K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.48 vs a range of $0.44–$2.14 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 8 sales; latest: Gilead Raday sold 14,130,000 shares on Jul 10, 2026.
- Latest filings: 6-K Oct 13, 2026; 6-K Oct 7, 2026; 6-K Sep 30, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RDHL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.50 | 0.51 | 0.48 | 0.48 | 84.72K |
| Oct 15, 2026 | 0.49 | 0.51 | 0.48 | 0.50 | 59.40K |
| Oct 14, 2026 | 0.50 | 0.51 | 0.48 | 0.49 | 84.70K |
| Oct 13, 2026 | 0.51 | 0.53 | 0.50 | 0.51 | 81.60K |
| Oct 12, 2026 | 0.54 | 0.56 | 0.51 | 0.53 | 70.00K |
| Oct 9, 2026 | 0.55 | 0.59 | 0.52 | 0.54 | 379.30K |
| Oct 8, 2026 | 0.50 | 0.69 | 0.44 | 0.58 | 15.75M |
| Oct 7, 2026 | 0.47 | 0.50 | 0.47 | 0.47 | 36.10K |
| Oct 6, 2026 | 0.50 | 0.50 | 0.47 | 0.48 | 57.90K |
| Oct 5, 2026 | 0.50 | 0.51 | 0.49 | 0.49 | 90.70K |
| Oct 2, 2026 | 0.51 | 0.51 | 0.49 | 0.50 | 130.20K |
| Oct 1, 2026 | 0.47 | 0.49 | 0.47 | 0.48 | 556.30K |
| Sep 30, 2026 | 0.48 | 0.50 | 0.48 | 0.48 | 217.90K |
| Sep 29, 2026 | 0.49 | 0.50 | 0.47 | 0.48 | 92.10K |
| Sep 28, 2026 | 0.50 | 0.52 | 0.49 | 0.51 | 89.60K |
| Sep 25, 2026 | 0.52 | 0.52 | 0.50 | 0.50 | 102.90K |
| Sep 24, 2026 | 0.54 | 0.56 | 0.52 | 0.52 | 89.40K |
| Sep 23, 2026 | 0.53 | 0.55 | 0.52 | 0.54 | 80.30K |
| Sep 22, 2026 | 0.55 | 0.57 | 0.52 | 0.54 | 200.70K |
| Sep 21, 2026 | 0.56 | 0.57 | 0.54 | 0.55 | 77.80K |
About RedHill Biopharma
RedHill Biopharma (RDHL) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in TEL AVIV, Israel. State of incorporation: Israel. Fiscal year ends —. SEC CIK 1553846.
RDHL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Dror Ben-Asher | Chief Executive Officer | Mar 18, 2026 |
| Shmuel Cabilly | Director | Mar 18, 2026 |
| Roni Mamluk | Director | Mar 18, 2026 |
| Kenneth Reed | Director | Mar 18, 2026 |
| Rick D Scruggs | Chief Commercial Officer | Mar 18, 2026 |
| Ofer Tsimchi | Director | Mar 19, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Dror Ben-Asher | Chief Executive Officer | Mar 18, 2026 |
| Adi Frish | Chief Corp & BD Officer | Mar 18, 2026 |
| Guy Joel Goldberg | Chief Business Officer | Mar 18, 2026 |
| Razi Ingber | Chief Financial Officer | Mar 18, 2026 |
| Gilead Raday | Chief Operating Officer | Jul 13, 2026 |
| Rick D Scruggs | Chief Commercial Officer | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 10, 2026 | Gilead Raday | Sale | 14,130,000 | — |
| Jul 10, 2026 | Gilead Raday | Sale | 14,130,000 | — |
| Jul 10, 2026 | Gilead Raday | Sale | 14,130,000 | — |
| Jul 10, 2026 | Gilead Raday | Sale | 14,130,000 | — |
| Apr 6, 2026 | Gilead Raday | Sale | 15,740,000 | — |
| Apr 6, 2026 | Gilead Raday | Sale | 15,740,000 | — |
| Apr 6, 2026 | Gilead Raday | Sale | 15,740,000 | — |
| Apr 6, 2026 | Gilead Raday | Sale | 15,740,000 | — |
RDHL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
RDHL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RDHL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.